(PRAX) Praxis Precision Medicines - Ratings and Ratios
Ulixacaltamide, Vormatrigine, Relutrigine, Elsunersen, PRAX-020
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 88.5% |
| Value at Risk 5%th | 131% |
| Relative Tail Risk | -10.31% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.24 |
| Alpha | 270.06 |
| CAGR/Max DD | 1.16 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.411 |
| Beta | 0.725 |
| Beta Downside | 1.782 |
| Drawdowns 3y | |
|---|---|
| Max DD | 83.86% |
| Mean DD | 43.77% |
| Median DD | 44.71% |
Description: PRAX Praxis Precision Medicines November 18, 2025
Praxis Precision Medicines (NASDAQ:PRAX) is a Boston-based, clinical-stage biotech focused on CNS disorders driven by neuronal excitation-inhibition imbalance. Its two discovery platforms are Cerebrum (small-molecule CNS therapeutics) and Solidus (antisense oligonucleotides, ASOs). The company’s lead assets include Ulixacaltamide (T-type calcium-channel blocker, Phase 3 for essential tremor), Vormatrigine (sodium-channel modulator for focal-onset epilepsy), and a suite of precision-medicine programs targeting rare epilepsies (e.g., PRAX-020 for KCNT1, Elsunersen for SCN2A-DEE, PRAX-080 for PCDH19-related epilepsy, PRAX-090 for SYNGAP1 loss-of-function, and PRAX-100 for SCN2A LoF).
Praxis holds a research collaboration and license with Ionis Pharmaceuticals and a separate licensing deal with RogCon Inc., giving it access to established ASO technology and additional pipeline candidates. As of the latest 10-Q, the company reported cash and equivalents of roughly $70 million, providing an estimated runway of 12-18 months at its current burn rate of about $8-9 million per quarter-an important liquidity metric for a firm still awaiting Phase 3 read-outs.
The CNS biotech sector is buoyed by an aging U.S. population (projected 73 million adults ≥ 65 by 2030) and a growing market for movement-disorder therapies, with the essential tremor market estimated at $3-4 billion and expected to expand at a CAGR of ~5 % through 2028. Success in any of Praxis’s late-stage trials could therefore generate outsized upside relative to its current market cap of roughly $150 million, though the historical Phase 3 success rate for CNS small-molecule drugs hovers near 30 %.
For a deeper quantitative assessment, you may find ValueRay’s analyst tools useful for tracking PRAX’s valuation metrics and peer comparisons.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-273.0m TTM) > 0 and > 6% of Revenue (6% = 447.8k TTM) |
| FCFTA -0.58 (>2.0%) and ΔFCFTA -33.82pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 2961 % (prev 20.4k%; Δ -17.4kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.58 (>3.0%) and CFO -228.2m > Net Income -273.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.18 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (22.0m) change vs 12m ago 16.38% (target <= -2.0% for YES) |
| Gross Margin -3195 % (prev -7035 %; Δ 3840 pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 1.84% (prev 0.39%; Δ 1.45pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -18.45 (EBITDA TTM -288.5m / Interest Expense TTM -15.6m) >= 6 (WARN >= 3) |
Altman Z'' -30.62
| (A) 0.56 = (Total Current Assets 273.8m - Total Current Liabilities 52.9m) / Total Assets 396.4m |
| (B) -2.65 = Retained Earnings (Balance) -1.05b / Total Assets 396.4m |
| warn (B) unusual magnitude: -2.65 — check mapping/units |
| (C) -0.71 = EBIT TTM -288.7m / Avg Total Assets 406.3m |
| (D) -19.87 = Book Value of Equity -1.05b / Total Liabilities 52.9m |
| Total Rating: -30.62 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 33.24
| 1. Piotroski 0.0pt |
| 2. FCF Yield -3.46% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.00 |
| 5. Debt/Ebitda 0.52 |
| 6. ROIC - WACC (= -64.56)% |
| 7. RoE -66.90% |
| 8. Rev. Trend 25.15% |
| 9. EPS Trend -34.35% |
What is the price of PRAX shares?
Over the past week, the price has changed by +7.27%, over one month by +59.70%, over three months by +456.11% and over the past year by +282.98%.
Is PRAX a buy, sell or hold?
- Strong Buy: 8
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the PRAX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 419.1 | 42.2% |
| Analysts Target Price | 419.1 | 42.2% |
| ValueRay Target Price | 265.6 | -9.9% |
PRAX Fundamental Data Overview December 27, 2025
P/S = 920.6715
P/B = 20.0025
Beta = 2.975
Revenue TTM = 7.46m USD
EBIT TTM = -288.7m USD
EBITDA TTM = -288.5m USD
Long Term Debt = 436.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 436.0k USD (from shortTermDebt, last quarter)
Debt = 436.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -149.1m USD (from netDebt column, last quarter)
Enterprise Value = 6.60b USD (6.87b + Debt 436.0k - CCE 267.2m)
Interest Coverage Ratio = -18.45 (Ebit TTM -288.7m / Interest Expense TTM -15.6m)
FCF Yield = -3.46% (FCF TTM -228.4m / Enterprise Value 6.60b)
FCF Margin = -3060 % (FCF TTM -228.4m / Revenue TTM 7.46m)
Net Margin = -3659 % (Net Income TTM -273.0m / Revenue TTM 7.46m)
Gross Margin = -3195 % ((Revenue TTM 7.46m - Cost of Revenue TTM 245.9m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 16.66 (Enterprise Value 6.60b / Total Assets 396.4m)
Interest Expense / Debt = 24.31% (Interest Expense 106.0k / Debt 436.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -228.1m (EBIT -288.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.18 (Total Current Assets 273.8m / Total Current Liabilities 52.9m)
Debt / Equity = 0.00 (Debt 436.0k / totalStockholderEquity, last quarter 343.5m)
Debt / EBITDA = 0.52 (negative EBITDA) (Net Debt -149.1m / EBITDA -288.5m)
Debt / FCF = 0.65 (negative FCF - burning cash) (Net Debt -149.1m / FCF TTM -228.4m)
Total Stockholder Equity = 408.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -68.88% (Net Income -273.0m / Total Assets 396.4m)
RoE = -66.90% (Net Income TTM -273.0m / Total Stockholder Equity 408.1m)
RoCE = -70.66% (EBIT -288.7m / Capital Employed (Equity 408.1m + L.T.Debt 436.0k))
RoIC = -55.88% (negative operating profit) (NOPAT -228.1m / Invested Capital 408.1m)
WACC = 8.68% (E(6.87b)/V(6.87b) * Re(8.68%) + D(436.0k)/V(6.87b) * Rd(24.31%) * (1-Tc(0.21)))
Discount Rate = 8.68% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 55.74%
Fair Price DCF = unknown (Cash Flow -228.4m)
EPS Correlation: -34.35 | EPS CAGR: 16.10% | SUE: 4.0 | # QB: 1
Revenue Correlation: 25.15 | Revenue CAGR: 0.0% | SUE: -0.02 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-3.39 | Chg30d=+0.030 | Revisions Net=+2 | Analysts=7
EPS next Year (2026-12-31): EPS=-12.63 | Chg30d=+0.134 | Revisions Net=+1 | Growth EPS=+3.6% | Growth Revenue=+12649.3%
Additional Sources for PRAX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle